Recent 8-K filings for PRLD

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 12, 2026 11:11 UTC earnings item 2.02item 7.01item 9.01

  Prelude Therapeutics Q1 net loss $10.4M ($0.13/sh); cash runway into Q2 2028 after $90M offering

source · PRLD on sec.gov